Skip to main content
Pfizer grants Biogen rights to neuropsychiatry candidate

Pfizer's neuropsychiatry candidate PF-04958242 was acquired by Biogen for $75 million upfront in a deal that could give Pfizer $515 million in milestones, plus royalties. Biogen plans to begin a Phase IIb study of the candidate for the treatment of cognitive impairment associated with schizophrenia later this year.

Full Story: